19:29 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Neuroendocrine tumors; lymphoma Cell culture and mouse studies suggest inhibiting SLC7A5 or SLC43A1 could help treat MYC-driven neuroblastoma and Burkitt’s lymphoma. In MYC-driven human neuroblastoma and Burkitt’s lymphoma cell lines, shRNA targeting SLC7A5 or...
21:20 , Feb 3, 2017 |  BC Week In Review  |  Company News

Therapeia, Telix deal

Therapeia granted Telix rights to ACD-101 to treat glioblastoma and an exclusive option to acquire Therapeia, which Telix plans to exercise in 2Q17. Telix said it expects the synthetic amino acid that targets solute carrier...